Show simple item record

AuthorTang, Patrick
AuthorHasan, Mohammad R
AuthorChemaitelly, Hiam
AuthorYassine, Hadi M
AuthorBenslimane, Fatiha M
AuthorAl Khatib, Hebah A
AuthorAlMukdad, Sawsan
AuthorCoyle, Peter
AuthorAyoub, Houssein H
AuthorAl Kanaani, Zaina
AuthorAl Kuwari, Einas
AuthorJeremijenko, Andrew
AuthorKaleeckal, Anvar Hassan
AuthorLatif, Ali Nizar
AuthorShaik, Riyazuddin Mohammad
AuthorAbdul Rahim, Hanan F
AuthorNasrallah, Gheyath K
AuthorAl Kuwari, Mohamed Ghaith
AuthorAl Romaihi, Hamad Eid
AuthorButt, Adeel A
AuthorAl-Thani, Mohamed H
AuthorAl Khal, Abdullatif
AuthorBertollini, Roberto
AuthorAbu-Raddad, Laith J
Available date2021-11-07T08:31:18Z
Publication Date2021-11-02
Publication NameNature Medicine
Identifierhttp://dx.doi.org/10.1038/s41591-021-01583-4
CitationTang, P., Hasan, M.R., Chemaitelly, H. et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med (2021). https://doi.org/10.1038/s41591-021-01583-4
ISSN1078-8956
URIhttp://hdl.handle.net/10576/24856
AbstractWith the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population. BNT162b2 effectiveness against any, symptomatic or asymptomatic, Delta infection was 45.3% (95% CI, 22.0-61.6%) ≥14 d after the first vaccine dose, but only 51.9% (95% CI, 47.0-56.4%) ≥14 d after the second dose, with 50% of fully vaccinated individuals receiving their second dose before 11 May 2021. Corresponding mRNA-1273 effectiveness ≥14 d after the first or second dose was 73.7% (95% CI, 58.1-83.5%) and 73.1% (95% CI, 67.5-77.8%), respectively. Notably, effectiveness against Delta-induced severe, critical or fatal disease was 93.4% (95% CI, 85.4-97.0%) for BNT162b2 and 96.1% (95% CI, 71.6-99.5%) for mRNA-1273 ≥ 14 d after the second dose. Our findings show robust effectiveness for both BNT162b2 and mRNA-1273 in preventing Delta hospitalization and death in Qatar's population, despite lower effectiveness in preventing infection, particularly for the BNT162b2 vaccine.
Languageen
PublisherNature Researc
SubjectBNT162b2
mRNA-1273
COVID-19
vaccine
TitleBNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
TypeArticle
ESSN1546-170X
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record